Precision psychiatry
We pioneer precision psychiatry through biomarker identification for personalized antidepressant development and therapy selection, enhancing treatment outcomes and improving clinical trials.
Our focus is depression
We address the low success rates of depression clinical trials by leveraging machine learning and deep learning to analyze EEG data, significantly improving the potential for successful outcomes.
The Brainify.AI platform
Our platform employs EEG data and advanced machine learning to boost clinical trial success. Our state-of-the-art solutions address the key challenges in a clinical trial: high placebo response, high heterogeneity, scalability and the subjectivity of questionnaires.
The need for precision psychiatry is evident
38% of patients fail to respond to currently available antidepressants.
300,000,000
Number of people suffering from depression worldwide
#1 cause of death
For individuals aged 15-44 in the U.S.
$1 trillion
Lost productivity every year, worldwide
In the News
Stay up to date with what is new with our project, the industry, and find out more about the upcoming products and events.
Brainify.AI CEO, Mariam Khayretdinova, presents latest results at MIT
Brainify.AI Welcomes Dr. Jim Doherty as New Advisory Board Member
Brainify.AI CEO to Pitch at HBS Healthcare Alumni Startup Showcase
Scientific publications
At Brainify.AI, we view our scientific work as the backbone of the project. Read more...